Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Verona Pharma (VRNA) to $60 from $42 and keeps a Buy rating on the ...

Verona Pharma (NASDAQ:VRNA – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $60.00 price target ...

In a remarkable display of market confidence, Verona Pharma (NASDAQ:VRNA)'s stock has surged to an all-time high, reaching a ...

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

Verona Pharma (NASDAQ:VRNA – Get Free Report) was upgraded by investment analysts at Roth Capital to a “strong-buy” rating in ...

In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against other Billionaire Joseph Edelman’s long-term stock picks. Joseph Edelman is a renowned figure ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

BTIG raised the firm’s price target on Verona Pharma (VRNA) to $77 from $51 and keeps a Buy rating on the shares. The company’s Q4 pre-announcement was “impressive”, with Ohtuvayre revenue ...

To participate, please dial one of the following numbers and ask to join the Verona Pharma call: Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 ...

30,134 people played the daily Crossword recently. Can you solve it faster than others?30,134 people played the daily Crossword recently. Can you solve it faster than others? Investing $10,000 in ...